162
Views
4
CrossRef citations to date
0
Altmetric
Review

Post-Transplant Maintenance Therapy for Patients with Acute Myeloid Leukemia: Current Approaches and the Need for More Trials

, , , ORCID Icon &
Pages 21-32 | Published online: 26 Jan 2021

References

  • The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–2207. doi:10.1056/NEJMoa1301689
  • Döhner H, Estey E, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–474.
  • Burnett A, Russell N, Hills R, et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015;125(25):3878–3885. doi:10.1182/blood-2015-01-623447
  • Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5):475–486. doi:10.1200/JCO.2010.30.2554
  • Terwijn M, van Putten W, Kelder A, van der Velden V, Brooimans R, Pabst T. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31(31):3889–3897. doi:10.1200/JCO.2012.45.9628
  • Ivey A, Hills R, Simpson MA, et al. Assessment of minimal residual disease in standard- risk AML. N Engl J Med. 2016;374:422–433. doi:10.1056/NEJMoa1507471
  • Freeman S, Hills R, Virgo P, et al. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. J Clin Oncol. 2018;36(15):1486–1497. doi:10.1200/JCO.2017.76.3425
  • Wingard J, Majhail N, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29(16):2230–2239. doi:10.1200/JCO.2010.33.7212
  • Bejanyan N, Weisdorf D, Logan B, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2015;21(3):454–459. doi:10.1016/j.bbmt.2014.11.007
  • Ganzel C, Sun Z, Cripe L, et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience. Am J Hematol. 2018;93:1074–1081. doi:10.1002/ajh.25162
  • Thanarajasingam G, Kim H, Cutler C, et al. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(12):1713–1718. doi:10.1016/j.bbmt.2013.09.011
  • Bazarbachi A, Schmid C, Labopin M, et al. Evaluation of trends and prognosis over time in patients with AML relapsing after allogeneic hematopoeitic cell transplant reveals improved survival for young patients in recent years. Clin Cancer Res. 2020b;3134.
  • Craddock C. Pharmacological methods to reduce disease recurrence. Hematology Am Soc Hematol Educ Program. 2013;2013:63–69. doi:10.1182/asheducation-2013.1.63
  • Choi J, Ritchey J, Prior J, et al. In vivo administration of hypomethylating agents mitigate graft-versus host disease without sacrificing graft-versus-leukemia. Blood. 2010;116(1):129–139. doi:10.1182/blood-2009-12-257253
  • Goodyear O, Dennis M, Jilani N, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012;119(14):3361–3369. doi:10.1182/blood-2011-09-377044
  • Mathew N, Baumgartner F, Braun L, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018;24(3):282–291. doi:10.1038/nm.4484
  • Armand P, Kim H, Zhang M, et al. Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant. 2012;18(2):280–288. doi:10.1016/j.bbmt.2011.07.024
  • Schlenk R, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358:1909–1918. doi:10.1056/NEJMoa074306
  • Walter R, Buckley S, Pagel J, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013;122(10):1813–1821. doi:10.1182/blood-2013-06-506725
  • Festuccia M, Deeg H, Gooley T, et al. Minimal identifiable disease and the role of conditioning intensity in hematopoietic cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia evolving from myelodysplastic syndrome. Biol Blood Marrow Transplant. 2016;22(7):1227–1233. doi:10.1016/j.bbmt.2016.03.029
  • Milano F, Gooley T, Wood B, et al. Cord blood transplant in patients with minimal residual disease. N Engl J Med. 2016;375:944–953. doi:10.1056/NEJMoa1602074
  • D’Souza A, Lee S, Zhu X, Pasquini M. Current use and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2017;23(9):1417–1421. doi:10.1016/j.bbmt.2017.05.035
  • Scott B, Pasquini M, Logan B, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35(11):1154–1161. doi:10.1200/JCO.2016.70.7091
  • Cruijsen M, Hobo W, van der Velden W, et al. Addition of 10-day decitabine to fludarabine/total body irradiation conditioning is feasible and induces tumor-associated antigen specific T cell responses. Biol Blood Marrow Transplant. 2016;22(6):1000–1008. doi:10.1016/j.bbmt.2016.02.003
  • Sánchez-Abarca L, Gutierrez-Cosio S, Santamaría C, et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood. 2010;115(1):107–121. doi:10.1182/blood-2009-03-210393
  • Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2012;26(3):381–389. doi:10.1038/leu.2011.234
  • Craddock C, Jilani N, Siddique S, et al. Tolerability and clinical activity of posttransplantation Azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial. Biol Blood Marrow Transplant. 2016;22(2):385–390. doi:10.1016/j.bbmt.2015.09.004
  • Guillaume T, Florent Malard F, Leonardo Magro L, et al. Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2019;54(11):1815–1826. doi:10.1038/s41409-019-0536-y
  • de Lima M, Giralt S, Thall P, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2010;116(23):5420–5431. doi:10.1002/cncr.25500
  • El-Cheikh J, Massoud R, Fares E, et al. Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT. Bone Marrow Transplant. 2017;52(6):918–921. doi:10.1038/bmt.2017.31
  • Oran B, de Lima M, Garcia-Manero G, et al. Maintenance with 5-azacytidine for acute myeloid leukemia and myelodysplastic syndrome patients. Blood. 2018;132(Supplement 1):971. doi:10.1182/blood-2018-99-111582
  • Platzbecker U, Middeke J, Sockel K, et al. Minimal-residual disease guided treatment with azacitidine in MDS/AML patients at imminent risk of relapse: results of the prospective RELAZA2 trial. Blood. 2017;130(Supplement 1):565.
  • Wei AH, Döhner H, Pocock C, et al. The QUAZAR AML-001 maintenance trial: results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in patients with acute myeloid leukemia (AML) in first remission. Blood. 2019;134(suppl2):LBA–3. doi:10.1182/blood-2019-132405
  • de Lima M, Oran B, Champlin R, et al. CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes. Biol Blood Marrow Transplant. 2018;24(10):2017–2024. doi:10.1016/j.bbmt.2018.06.016
  • Pusic I, Choi J, Fiala M, et al. Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2015;21(10):1761–1769. doi:10.1016/j.bbmt.2015.05.026
  • Platzbecker U, Middeke J, Sockel K, et al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, Phase 2 trial. Lancet Oncol. 2018;19(12):1668–1679. doi:10.1016/S1470-2045(18)30580-1
  • Stahl M, Gore S, Vey N, Prebet T. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Investig Drugs. 2016;25(3):307–317. doi:10.1517/13543784.2016.1146251
  • Bug G, Burchert A, Wagner E-M, et al. Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial). Leukemia. 2017;31(11):2523–2525. doi:10.1038/leu.2017.242
  • Shen L, Pili R. Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy. Oncoimmunology. 2012;1(6):948–950. doi:10.4161/onci.20306
  • Brunet S, Labopin M, Esteve J, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol. 2012;30(7):735–741. doi:10.1200/JCO.2011.36.9868
  • Kayser S, Dohner K, Krauter J, et al. Impact of allogeneic transplantation from matched related and unrelated donors on clinical outcome in younger adult AML patients with FLT3 internal tandem duplications. Blood. 2010;116(21):909. doi:10.1182/blood.V116.21.909.909
  • Sengsayadeth S, Jagasia M, Engelhardt B, et al. Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Bone Marrow Transplant. 2012;47(12):1535–1537. doi:10.1038/bmt.2012.88
  • Deol A, Sengsayadeth S, Ahn K, et al. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016;122(19):3005–3014. doi:10.1002/cncr.30140
  • Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
  • Sakaguchi M, Yamaguchi H, Najima Y, et al. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. Blood Adv. 2018;2(20):2744–2754. doi:10.1182/bloodadvances.2018020305
  • Straube J, Ling V, Hill G, Lane S. The impact of age, NPM1mut, and FLT3ITD allelic ratio in patients with acute myeloid leukemia. Blood. 2018;131(10):1148–1153. doi:10.1182/blood-2017-09-807438
  • Bazarbachi A, Bug G, Baron F, et al. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow. Haematologica. 2020a;105(6):1507–1516. doi:10.3324/haematol.2019.243410
  • Schuurhuis G, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275–1291. doi:10.1182/blood-2017-09-801498
  • Antar, A., Kharfan-Dabaja, M, Mahfouz, R, & Bazarbachi, A. Sorafenib maintenance appears safe and improves clinical outcomes in FLT3-ITD acute myeloid leukemia after allogeneic hematopoietic cell transplantation. Clin Lymphoma Myeloma Leuk. 2015;15(5):298–302.
  • Borthakur G, Kantarjian H, Farhad Ravandi F, et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. 2011;96(1):62–68. doi:10.3324/haematol.2010.030452
  • Brunner A, Li S, Fathi A, et al. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016;175(3):496–504. doi:10.1111/bjh.14260
  • Battipaglia G, Ruggeri A, Massoud R, et al. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. Cancer. 2017;123(15):2867–2874. doi:10.1002/cncr.30680
  • Battipaglia G, Massoud R, Ahmed S, et al. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3 mutated acute myeloid leukemia: an update. Clin Lymphoma Myeloma Leuk. 2019;19(8):506–508. doi:10.1016/j.clml.2019.04.004
  • Chen Y, Li S, Lane A, et al. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant. 2014;20(12):2042–2048. doi:10.1016/j.bbmt.2014.09.007
  • Sammons S, Pratz K, Smith B, Karp J, Emadi A. Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant. Am J Hematol. 2014;89(9):936–938. doi:10.1002/ajh.23782
  • Antar A, Kharfan-Dabaja M, Mahfouz R, Bazarbachi A. Sorafenib maintenance appears safe and improves clinical outcomes in FLT3-ITD acute myeloid leukemia after allogeneic hematopoietic cell transplantation. Clin Lymphoma Myeloma Leuk. 2015;15(5):298–302. doi:10.1016/j.clml.2014.12.005
  • Pratz K, Rudek M, Smith B, et al. Prospective study of peri-transplant use of sorafenib as remission maintenance for FLT3-ITD patients undergoing allogeneic transplantation. Biol Blood Marrow Transplant. 2020;26(2):300–306. doi:10.1016/j.bbmt.2019.09.023
  • Bazarbachi A, Myriam Labopin M, Battipaglia G, et al. Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party. Haematologica. 2019;104(9):e398–e401. doi:10.3324/haematol.2018.211615
  • Bazarbachi A, Lab M, Battipaglia G, et al. Allogeneic stem cell transplantation for FLT3-mutated acute myeloid leukemia: in vivo T-cell depletion and posttransplant sorafenib maintenance improve survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant. Clinical Hematology International. 2019:58–74. doi:10.2991/chi.d.190310.001
  • Burchert A, Bug G, Fritz L, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3–internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993–3002. doi:10.1200/JCO.19.03345
  • Xuan L, Wang Y, Huang F, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020 Sep;21(9):1201–1212.
  • Stone R, Mandrekar S, Sanford B, Laumann K, Geyer S, Bloomfield C. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454–464. doi:10.1056/NEJMoa1614359
  • Schlenk R, Weber D, Fiedler W, Salih H, Wulf G, Salwender H. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019;133(8):840–851. doi:10.1182/blood-2018-08-869453
  • Levis M, Brown P, Smith B, Stine A, Pham R, Stone R. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006;108(10):3477–3483. doi:10.1182/blood-2006-04-015743
  • Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015;90(4):276–281. doi:10.1002/ajh.23924
  • Maziarz R, Patnaik M, Scott B, Mohan S, Deol A, Rowley S. A phase 2 randomized trial investigating standard of care 6 midostaurin after allogeneic stem cell-transplant in FLT3-ITD–mutated AML. Blood. 2018;132(Supplement 1):662. doi:10.1182/blood-2018-99-113582
  • Smith C, Wang Q, Chin C, Salerno S, Damon L, Levis M. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485(7397):260–263. doi:10.1038/nature11016
  • Perl A, Altman J, Cortes J, Smith C, Litzow M, Baer M. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: A multicentre, first-in-human, open-label, Phase 1–2 study. Lancet Oncol. 2017;18(8):1061–1075. doi:10.1016/S1470-2045(17)30416-3
  • Sandmaier B, Khaled S, Betul Oran B, Gammon G, Trone D, Frankfurt O. Results of a phase 1 study of quizartinib (AC220) as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic cell transplantation. Blood. 2014;124(21):428. doi:10.1182/blood.V124.21.428.428
  • Smith C, Paguirigan A, Jeschke G, Lin K, Massi E, Theodore Tarver T. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood. 2017;130(1):48–58. doi:10.1182/blood-2016-04-711820
  • Galanis A, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood. 2014;123(1):94–100. doi:10.1182/blood-2013-10-529313
  • Heisterkamp N, Jenster G, Hoeve J, Zovich D, Pattengale P, Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature. 1990;344(6263):251–253. doi:10.1038/344251a0
  • Li L, Piloto O, Nguyen H, Greenberg K, Takamiya K, Racke F. Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. Blood. 2008;111(7):3849–3858. doi:10.1182/blood-2007-08-109942
  • Jan M, Snyder T, Corces-Zimmerman M, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med. 2012;4(149):149ra118. doi:10.1126/scitranslmed.3004315
  • Roboz G, DiNardo C, Stein E, de Botton S, Mims A, Prince G. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020;135(7):463–471. doi:10.1182/blood.2019002140
  • Stein E, DiNardo C, Pollyea D, Fathi A, Roboz G, Altman J. Enasidenib in mutant IDH2 relapsed for refractory AML. Blood. 2017;130(6):722–731. doi:10.1182/blood-2017-04-779405
  • Uchida A, Isobe Y, Asano J, Uemura Y, Hoshikawa M, Takagi M. Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements. Haematologica. 2019;104(7):1417–1421. doi:10.3324/haematol.2018.204958
  • Pollyea D, Stevens B, Jones C, Winters A, Pei S, Minhajuddin M. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018;24(12):1859–1866. doi:10.1038/s41591-018-0233-1
  • DiNardo C, Wei A. How I treat acute myeloid leukemia in the era of new drugs. Blood. 2020;135(2):85–96. doi:10.1182/blood.2019001239
  • Fukushima N, Minami Y, Kakiuchi S, Kuwatsuka Y, Hayakawa F, Jamieson C. Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci. 2016;107(10):1422–1429. doi:10.1111/cas.13019
  • Terao T, Minami Y. Targeting hedgehog (Hh) pathway for the acute myeloid leukemia treatment. Cells. 2019;8(4):312. doi:10.3390/cells8040312
  • Cortes J, Heidel F, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33(2):379–389. doi:10.1038/s41375-018-0312-9
  • Middeke J, Fang M, Cornelissen J, Mohr B, Appelbaum F, Stadler M. Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Blood. 2014;123(19):2960–2967. doi:10.1182/blood-2013-12-544957
  • Sallman D, DeZern A, Garcia-Manero G, Steensma D, Roboz G, Sekeres M. Phase 2 results of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML). Blood. 2019;134(Supplement_1):676. doi:10.1182/blood-2019-131055
  • Oshikawa G, Kakihana K, Saito M, Aoki J, Najima Y, Kobayashi T. Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia. Br J Haematol. 2015;169(5):756–759. doi:10.1111/bjh.13248
  • Kadia T, Cortes J, Ghorab A, Ravandi F, Jabbour E, Guastad N. Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients. J Clin Oncol. 2018;36(15_suppl):7014. doi:10.1200/JCO.2018.36.15_suppl.7014
  • Sockel K, Bornhaeuser M, Mischak-Weissinger E, Trenschel R, Wermke M, Unzicker C. Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial. Haematologica. 2012;97(9):e34–5. doi:10.3324/haematol.2012.067629
  • Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009;113(7):1581–1588. doi:10.1182/blood-2008-07-168468
  • Davids M, Kim H, Bachireddy P, Costello C, Liguori R, Savell A. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375(2):143–153. doi:10.1056/NEJMoa1601202
  • Albring J, Inselmann S, Sauer T, Schliemann C, Altvater B, Kailayangiri S. PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation. Bone Marrow Transplant. 2017;52(2):317–320. doi:10.1038/bmt.2016.274
  • Walter R, Gooley T, Wood B, Milano F, Fang M, Sorror M. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29(9):1190–1197. doi:10.1200/JCO.2010.31.8121
  • Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132(16):1703–1713. doi:10.1182/blood-2018-02-829911
  • Kim T, Ho Moon J, Ahn J, Kim Y, Lee S, Ahn S. Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse. Blood. 2018;132(15):1604–1613. doi:10.1182/blood-2018-04-848028